Zoetis Inc. (NYSE:ZTS) Shares Sold by Argentarii LLC

Argentarii LLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 23.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,072 shares of the company's stock after selling 1,844 shares during the quarter. Argentarii LLC's holdings in Zoetis were worth $1,000,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ZTS. HUB Investment Partners LLC boosted its stake in shares of Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after purchasing an additional 62 shares during the period. Coppell Advisory Solutions LLC boosted its position in Zoetis by 18.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after buying an additional 64 shares during the period. Ironwood Investment Management LLC grew its stake in shares of Zoetis by 0.8% in the fourth quarter. Ironwood Investment Management LLC now owns 8,354 shares of the company's stock worth $1,361,000 after acquiring an additional 68 shares in the last quarter. Legacy Financial Advisors Inc. grew its stake in shares of Zoetis by 5.8% in the fourth quarter. Legacy Financial Advisors Inc. now owns 1,282 shares of the company's stock worth $209,000 after acquiring an additional 70 shares in the last quarter. Finally, Broadway Wealth Solutions Inc. increased its position in shares of Zoetis by 4.4% during the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after acquiring an additional 73 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.18% of the company's stock.

Analysts Set New Price Targets

ZTS has been the subject of several analyst reports. UBS Group lowered their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Piper Sandler upped their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $212.13.

Zoetis Stock Up 0.1%

Zoetis stock traded up $0.11 during mid-day trading on Friday, hitting $159.19. The company had a trading volume of 1,375,164 shares, compared to its average volume of 2,572,771. The stock has a market cap of $70.87 billion, a price-to-earnings ratio of 28.58, a PEG ratio of 2.64 and a beta of 0.91. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The business has a fifty day moving average of $161.16 and a 200 day moving average of $162.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same period last year, the firm posted $1.38 EPS. The company's revenue was up 1.4% on a year-over-year basis. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.26%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.